EOLS - Evolus GAAP EPS of -$0.23 misses by $0.02 revenue of $43.65M misses by $0.17M
2023-03-08 16:12:35 ET
- Evolus press release ( NASDAQ: EOLS ): Q4 GAAP EPS of -$0.23 misses by $0.02 .
- Revenue of $43.65M (+25.9% Y/Y) misses by $0.17M .
- Outlook: Evolus continues to expect total net revenues for full year 2023 to be between $180 million and $190 million, representing year-over-year growth of 21% to 28% and more than double the estimated growth rate of the aesthetic neurotoxin market. The company also assumes a return to historical seasonal revenue patterns.
- The company expects its adjusted gross profit margin 1 for the full year 2023 to be between 68% and 71% reflecting the new lower settlement royalty rate that became effective in September 2022.
- The company continues to expect full-year non-GAAP operating expenses 1 to be between $145 million and $150 million.
- Evolus expects non-GAAP operating income 1 to be positive in the fourth quarter of 2023 and continues to project its existing cash balance will fund current operations, eliminating the need for additional capital.
- The company projects its total net revenue 1 can reach $500 million by 2028, a 22% compound annual growth rate. This revenue projection excludes expansion of the label for Jeuveau ® and Nuceiva ® or portfolio additions.
For further details see:
Evolus GAAP EPS of -$0.23 misses by $0.02, revenue of $43.65M misses by $0.17M